RSS   Newsletter   Contact   Advertise with us
Post Online Media

Pfenex chairman William R. Rohn to step down

PfenexPfenex, a clinical-stage biotechnology company, announced that William R. Rohn will not stand for reelection as a board member and will retire as chairman on May 5, 2017.

Mr. Rohn joined Company's board of directors as the chairman in connection with Pfenex’s initial public offering in July 2014.

Most recently, Mr. Rohn served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005.

Mr. Rohn also held various management positions with IDEC Pharmaceuticals, a biotechnology company, including: President and Chief Operating Officer from 1998 to 2003, Senior Vice President, Commercial Operations from 1996 to 1998 and Senior Vice President, Commercial and Corporate Development from 1993 to 1996.

He also held various management positions with Adria Laboratories, a pharmaceutical company acquired by Pfizer Inc., including: Senior Vice President of Commercial Operations from 1991 to 1993 and Vice President of Business Development and Licensing from 1985 to 1990.

Mr. Rohn currently serves on the board of directors of Hansen Medical, a medical device company.

Mr. Rohn previously served on the boards of Intellikine, a pharmaceutical company acquired by Takeda America Holdings, Cerus Corporation, a biomedical products company, Elan Corporation, a pharmaceutical company acquired by Perrigo Company, Metabasis Therapeutics, a biopharmaceutical company that merged with Ligand Pharmaceuticals , and Pharmacyclics, a pharmaceutical company.

He holds a Bachelor’s degree in Marketing from Michigan State University and has completed graduate-level coursework in Business Administration at Indiana State University.


 LATEST MOVES FROM California 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy